Winning
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
All you have to do is look at the founders. Not so much Helix's founders but the company they became incorporated with. The person that put that incorporation deal together currently sits in prison for stock fraud. The funny thing is that Helix owes his company 650K now. Blah, blah, blah, blah.
I could go on and on but it's a waste of my time. I've licked my wounds, so to speak. Still have 100K shares sitting in case a miracle happens. You never know with these subbys.
Anytime you gain patent protection for your intellectual property, it's always a big deal for small companies like this one that have good products. Just awaiting the announcement of their latest victory from last week.
That 'something' has been brewing for 8 days now.
10Q out. The pain continues
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7876287
I'm glad they didn't PR what happened this week, heading into a long weekend. Would of taken away the potential strength. Hopefully, they do on Monday or Tuesday.
I'm considering slapping it again tomorrow if the news I'm starring at isn't out yet. I'd be breaking my own trading rules though. Ha!
I need to spend tomorrow doing additional DD here. I haven't done as much as I normally do before making an entry. There's a broken rule right there.
Yes, I am aware of that. I'm talking about the patent for it.
System and Process for Forming Micro Bubbles in Liquid, which has been awaiting approval since 2008
Indeed it is =idfix=. Just waiting for the official announcement.
The next patent to be approved
Clean Water Scientifics' patent pending technology is a device known as the Add-o-mizer, a cylindrical unit wherein liquid and gas are mixed under high pressure. Inside the unit the liquid and gas are mixed in a fashion to dissolve the gas into the liquid. Upon release from the unit, the gas appears in a small bubble formation within the liquid. This process has been used and proven very effective in water treatment, water purification, and water oxygenation.
I slapped it for another 50K. Gonna be an interesting week.
New development should be announced this week. Unless management decides to sit on it.
If more funds become available today, I'll slap it again.
Something special is on the horizon. Confirmed.
How about a patent approval for the Add-O-Mizer?
1.9 mill was me. I see its still at 9. Oh well. Worth a shot.
No worries. Thanks. One more thing, if you will. How many MM's are on the Ask right now. Gonna try and take em out.
The float from March 2010. Wondering if there was an updated one.
What is the current float?
Been sitting on the 8's all morning. May have to slap the ask.
For the sake of discussion, if there was one piece of news you'd want to see released by SLRW, what would it be? And how do you think it would effect the PPS.
I will finally enter into this tomorrow. Been watching it since last November, waiting for a specific scenario. Would like to get in at .0008 or .0009. We'll see what happens.
Short interest picking up for April. 30% so far
20110418|SLRW|238000|0| 263578|O
20110415|SLRW|416977|0| 500977|O
20110414|SLRW|62555 |0| 577555|O
20110413|SLRW|2000000|0|2840000|O
20110412|SLRW 0 1706111
20110411|SLRW|3169616|0|8033389|O
20110408|SLRW|1080000|0|3022350|O
20110407|SLRW|720000 |0|1990088|O
20110406|SLRW 0 104000
20110405|SLRW 0 3359962
20110404|SLRW|104834|0| 1547348|O
20110401|SLRW 0 2060289
short interest
7,791,982
daily volume
26,005,647
= 30% Short Interest
Just make sure you hold onto your shares this week.
I will be entering a large position tomorrow. A little birdie landed on my window sill and sang something sweet.
Get ready everybody.
Data Points Show CROs on the Brink of Recovery
http://finance.yahoo.com/news/Data-Points-Show-CROs-on-the-ms-739284541.html?x=0&.v=1
Lauren Migliore, On Friday April 15, 2011, 7:00 am EDT
"We think the contract research industry is on the brink of recovery. After economic uncertainty and frozen credit markets conspired to create a sharp pullback in drug development spending, bookings appear to be back on track and the crippling cancellations witnessed in 2009 have normalized. We have long maintained that the slowdown in research-and-development spending was temporary due to the fundamental need to drive new therapies through clinical trials. We expect capacity rationalization and strong bookings trends to spur top-line gains for the major contract research organizations (CROs) in 2011. With pharmaceutical firms in need of replenishing their pipelines while also cutting costs, we think the top players will continue to expand market share in this high-growth industry.
Improvement in Future Trial Demand Positions CROs for a Rebound
A dramatic slowdown in drug development spending has wreaked havoc on the leading contract research organizations and their income statements during the last two years. Drugmakers looking to rein in costs decided to delay development spending and cancel trials outright from late 2008 through 2009. These spending delays were then compounded by large pharmaceutical consolidation, reduction in biotech funding, and uncertainty surrounding health-care reform. Although bookings have rebounded and cancellations have moderated compared to the crippling amounts experienced in 2009, quarterly performance for CROs is highly contingent upon new business wins in prior quarters. However, while the financial performance of the CRO industry still remains below historical levels, the vast majority of firms witnessed both sequential and year-over-year revenue growth during the fourth quarter. All the CROs in our coverage universe turned in book/bill ratios of at least 1.0 during the fourth quarter, signaling that growth will return to the CRO industry in 2011. Strong new bookings are a testament to our thesis that drugmakers are beginning to unfreeze their pipelines and limit cancellations. We think the CRO industry has turned a corner, as evidenced by a resurgence in new business activity and relatively stable volume and pricing during the last year. Considering the compelling value proposition offered by the CRO model, we expect drugmakers to outsource an increasing portion of their R&D budgets to a select group of preferred providers. We think the industry's leading players--with their global scale and therapeutic breadth--will benefit from these trends over the long run.
To see graphics associated with this article, click here:
http://news.morningstar.com/articlenet/article.aspx?id=376626
Compelling Investment Opportunities Remain in the CRO Industry
While improving performance has helped lift the shares of CROs in recent months, four firms still carry our 4-star rating. ICON (NasdaqGS:ICLR - News) took a fourth-quarter hit when management announced its projections for a longer-than-expected delay in demand recovery. While near-term profitability pressure has a small impact on our valuation of the firm, we believe that ICON's troubles are simply a timing issue and that the firm's long-run prospects remain intact. Shares of Charles River (NYSE:CRL - News) also remain undervalued as continued declines in preclinical services and management concerns following the company's bungled acquisition of WuXi PharmaTech (NYSE:WX - News) weigh on the stock. We think the market is undervaluing the cash flow power of Charles River's RMS business, and the firm's PCS franchise should provide substantial upside for investors as demand comes back on line. Furthermore, management has been on its best behavior following shareholder backlash surrounding the highly unpopular deal. We approve of management's commitment to returning value to shareholders through substantial share repurchases.
Sales Growth Reflects Stabilizing Market Conditions in Early-Stage Drug Development
The earnings reports from Covance (NYSE:CVD - News) and Charles River continue to reflect a sustained period of slow bookings and negative pricing trends, but the firms' projections for 2011 signal that the worst may be over for early-stage drug developers. Capacity underutilization continues to be the culprit behind persistent underperformance in toxicology, as drugmakers scrutinize expenses and focus resources on late-stage candidates that offer quicker revenue potential. However, the major toxicology players have all recently announced plans to reduce capacity, which should improve pricing dynamics as drugmakers begin to reinvigorate their preclinical activities. Facility rationalization should buoy the financial performance of early-stage CROs in 2011. We expect the financial performance of the two largest players in this segment, Charles River and Covance, will fall near the top range of management's guidance for the year as cost control and aggressive share repurchases magnify the impact of top-line gains on the bottom line.
After two years of top-line declines, Charles River experienced sequential revenue growth of 2.0% in the fourth quarter. Covance, which has fared better than Charles River during the downturn because of its success in signing large-scale deals, turned in positive top-line growth on both a year-over-year and sequential basis. In our opinion, sequential sales growth in the fourth quarter reflects stabilizing market conditions in early-stage drug development. We think demand normalization and capacity reduction could help Charles River see low-single-digit growth in 2011. We expect Covance to earn high-single-digit growth in 2011 thanks to new business wins from the firm's strategic alliance with Sanofi-Aventis (NYSE:SNY - News). The firm has been highly successful at locking in long-term partnerships with some of the world's largest drugmakers, and we think new strategic alliances could provide additional upside potential this year for Covance. For instance, we expect Pfizer (NYSE:PFE - News) to substantially up its rate of outsourcing following the firm's decision to streamline its research-and-development activities earlier this year.
Late-Stage CROs Turn in Mixed Results in the Fourth Quarter, but Earnings Pressure Looks Temporary
Late-stage development has held up relatively well compared to early-stage activities, which has helped most CROs that focus on Phase II-IV trials continue to generate growth amid the downturn. Although top-line gains continued for most firms during the fourth quarter, several company-specific issues weighed on profitability during the period. Despite pressure on profits, booking trends remained favorable in late 2010 with the major CROs' reporting book/bill ratios of at least 1.0 during the quarter. Although new business wins are encouraging, we are wary of the slower pace at which bookings may translate into revenue. For instance, Parexel (NasdaqGS:PRXL - News) lowered its outlook for the remainder of fiscal 2011 as it became apparent that management's initial projections for backlog conversion were too aggressive. It appears the industry's shift from a transactional approach toward strategic alliances has caused traditional revenue burn-off models to become less reliable. CROs are being brought to the table earlier in the clinical trial design process, and trials are increasing in size, complexity, and global breadth. While these dynamics bode well for the major players' long-term growth and profitability, an unusual amount of projects in startup mode may weigh on results in the near term. We think the margin pressure seen by late-stage CROs is a temporary growing pain associated with transitioning into a long-term strategic model. We expect these headwinds to be short-lived as production levels normalize. Total industry backlog grew 20% from 2009, primarily driven by several major deals announced during the year."
Doesn't matter if the stock price is already low. If certain situations line up the way they did with NWCI, the short sellers that watch this stock, will short it when the opportunity presents itself. They did the exact same thing last December. Once it hit the .90's, which is a big resistance point, they knew there wouldn't be any buying support. Once they saw buying volume cease at .93, the bid fall back into the mid .80's and multiple MM's start clustering around .93, they knew the rise was finished and they attacked it accordingly. Add to that, the wide spreads and thin bids, this was a short seller's dream scenario. They went to town on this thing. 32% of all volume was short selling. Somebody made a lot of money.
It'll gradually recover. Head back to the .70's and .80's and hover around there for a while, where we have strong support, until another catalyst comes along. Hopefully, the next time we hit the .90's it'll be on solid news and when the short sellers won't be presented with the same opportunity and we'll see a $1.00 again.
Being that John Fife, when he was a hedge fund manager, was convicted of stock fraud, one would think that he'd be on their short list.
http://www.sec.gov/litigation/complaints/2007/comp19972.pdf
http://www.sec.gov/litigation/litreleases/2007/lr20250.htm
Accumulation like this is always good. I imagine that the bids and asks will start to become very thin. Volatility will probably increase, but most likely for the better. Big money usually makes some entries then, but at the low end, so they'll probably knock it back down to get in cheap, but it'll go back up just as quick. Just like Newcardio inc.
Timing is working out well as the majority of my shares are becoming long term. Now I'm just thinking out loud. Cheers!
The only noise I hear is John Fife over at St George licking his lips getting ready for a 2nd helping of the HLXW feast of defaults.
If NIR goes down the tubes, EPGL's debt will be taken over by somebody else. EPGL will never see Caveat Emptor. That's a a dream of yours and yours alone.
Ribotsky's world is caving in on him. Neither him nor NIR are long for this world. There will be no erstructure deal with NIR since NIR won't be holding the debt much longer. Whoever buys EPGL's debt after NIR gets broken up will determine what happens next. That's what I'm waiting for. Caveat Emptor status will not occur.
Study results to be showcased in Guided Audio Poster Tour at the American Diabetes Association Annual Scientific Session
NewCardio Study Shows my3KG Improves Diagnostic Accuracy in Diabetics with Acute Myocardial Infarction
Study results to be showcased in Guided Audio Poster Tour at the American Diabetes Association Annual Scientific Session
SANTA CLARA, CA (April 7, 2011) - PR Newswire - NewCardio, Inc., (OTC BB: NWCI) a cardiac diagnostic technology provider, announced today that the Company has been invited by the American Diabetes Association (ADA) to present the results of a key study showing that NewCardio's urgent care solution, my3KG™, had substantially greater accuracy than expert cardiologists' interpretation of standard 12-lead ECG (12L ECG) in diagnosing Acute Myocardial Infarction (AMI) in diabetic patients. The presentation will be made at the 71st Annual ADA Scientific Sessions to be held in San Diego, CA, June 24-28, 2011. In addition, the ADA has selected this presentation to be showcased in the Guided Audio Poster Tour, which features expert moderators that share their perspectives with attendees, highlighting novel and important developments in the field.
Dr. Ihor Gussak, MD, PhD, NewCardio's Chief Medical Officer, commented, "We are delighted to present our study results at this important gathering of diabetes experts, and particularly pleased that the ADA program committee chose to feature our presentation in a moderated poster session. Accurate and timely AMI diagnosis is a matter of great concern for diabetologists, and we believe our results show that my3KG can play a major role in solving it. The moderated poster session provides the opportunity to present our results directly to leading diabetes experts, and have one-on-one interactions that will allow us to discuss and explain the importance of our results in detail."
Study Background and Results
Diabetics with AMI represent a very large and growing patient group, and currently affect over 10% of adults in the US. Moreover, the incidence of AMI is two to four times greater in diabetics than in the general population, according to ADA and American Heart Association statistics. Accurate and timely diagnosis of AMI is notoriously difficult in diabetics, largely because the standard 12L ECG is often inaccurate, inconclusive or non-diagnostic in this patient group. To address this problem, investigators at the University of Kansas Medical Center, in collaboration with NewCardio physician-scientists, obtained detailed clinical and 12L ECG data on 155 consecutive diabetic patients with suspected AMI, and evaluated the diagnostic performance of my3KG in this patient group.
The study showed that my3KG had 42% greater sensitivity than expert cardiologist interpretation of 12L ECG for early detection of AMI, with equal or better specificity. Based on these important results, NewCardio believes use of my3KG in this patient group may facilitate more accurate and timely diagnosis of AMI in diabetic patients, thereby improving clinical outcomes.
NewCardio's innovative 3-D ECG platform technology dramatically improves the accuracy and significantly increases the diagnostic value of the standard 12L ECG. NewCardio is developing the my3KG solution for urgent diagnosis of serious cardiac conditions, including AMI. In clinical studies to date, the my3KG has shown substantially improved diagnostic accuracy relative to the standard 12L ECG, particularly in the most diagnostically challenging patients (such as those with diabetes and electrical conduction abnormalities). Accordingly, the Company believes that its innovative my3kg solution will substantially improve diagnostic timing and accuracy in life-threatening cardiac conditions, and will thereby improve clinical outcomes for a broad range of cardiac patients. The my3KG is not currently marketed for sale in the U.S. The Company intends to file an application for 510(k) approval with the FDA in 2011/2012.
About the American Diabetes Association
The ADA is a volunteer-driven organization based in Alexandria, VA, with affiliate offices across the U.S. The mission of the ADA is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. To fulfill this mission, the Association funds research, publishes scientific findings, provides information and other services to people with diabetes, their families, health professionals and the public. The Association is also actively involved in advocating for scientific research and for the rights of people with diabetes. The Association acts on its mission through a number of critical programs and activities that are directed to a broad range of constituents, including consumers, research scientists, health care professionals, corporations and communities.
.
Its at a no-bid and a .0002 ask.
Everybody is waiting for the ask to hit .0001
As soon as it does, the starter pistol will fire.
NWCI: Confirmed uptrend while heading into an FDA sponsored conference next week. Accumulation has decimated the float over a 9 month period. Recently passed its 200 day moving average.
Newcardio's chart is available on it's iHub page
http://investorshub.advfn.com/boards/board.aspx?board_id=13573
NWCI Newcardio Inc continues it's uptrend after surpassing it's 200 day MMA, while it's 9 month accumulation continues. Float is quietly disappearing.
Yes, that hippie has a Helix Turbine from Helix. One that he bought quite a while ago. When Helix had a manufacturer and an inventory and a was a functioning company.
All that matters right now, is the state of the company at the PRESENT time. The most important piece of info, that everybody knows, is that at present date, they do not have a manufacturer. Nor do they have an inventory. Yes, they have a product that can be built. But, they have to have the money to build it and a company to build it for them. At present date, they have neither. Hence why they lost the OMRF deal and the Solar Blue deal.
With their current turmoil, the only way they achieve this is through a strategic partner. Or though, perhaps, another company franchising out the product and using their own manufacturer, resulting in royalty fees to Helix.
Until then, any info of who has a Helix brand turbine right now is completely irrelevant. Unless there is an article that shows they can manufacture their turbines at present date, there will be no forward movement.
Right now, instead of looking at who or what has the Helix brand turbine and other useless information, you all should be looking at Tilton and trying to find out 'why' he took this position. What are his incentives? Nobody takes the CEO position of a severely troubled company unless they have some sort of plan. That's where the goodies are.
There's a email going around pumping it from TheLottoPick.com.
NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development
Study shows NewCardio's novel intelligent ECG selection algorithm substantially improves study power in clinical drug studies
SANTA CLARA, Calif., March 31, 2011 /PRNewswire/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiovascular diagnostic solutions developer, announced today that the Company has been invited to present the results of a recent QTinno ® performance study at an upcoming conference entitled "Cardiovascular Safety in Drug Development: State-of-the-Art Assessments," sponsored by the U.S. Food and Drug Administration (FDA), the Cardiac Safety Research Consortium (CSRC) and the Heart Rhythm Society. The conference will be held in Washington, DC, on April 14-15, 2011.
The NewCardio study shows that QTinno's intelligent ECG selection and extraction provides accurate and optimized, consistent and automated selection of electrocardiograms (ECGs) from continuous 24 hour ECG recordings (Holter monitors), leading to improved study power and a substantial reduction in the number of study subjects needed to achieve the desired study power in early Phase QT studies, to include Thorough QT studies (TQTS). The results will be presented by Dr. Samuel George, NewCardio's Senior Medical Advisor, on behalf of NewCardio co-investigators Drs. Ihor Gussak and Branislav Vajdic. The study was done in collaboration with physician-scientists from a major pharmaceutical partner.
The study that will be presented at the FDA/CSRC/HRS conference addresses the need for reliable and reproducible ECG selection from Holter monitors. At present, the user visually selects three 10-second ECGs from the recording within five minutes of each designated study time point, a labor-intensive approach that is prone to error, increased variability and low reproducibility. NewCardio developed a novel "intelligent" ECG selection algorithm that evaluates the entire 10-minute window around the designated time point and selects the lowest noise and most stable ECGs in the window. The study shows NewCardio's intelligent ECG selection method yields more accurate and precise data than visual ECG selection, resulting in a substantial improvement in study power, and a large reduction in the number of study subjects needed to achieve the desired power. This proprietary advancement will allow sponsors to see significant cost reductions from studies, not just from the fully automated ECG analysis QTinno provides, but also because they will have the ability to conduct the study with fewer study subjects.
Dr. Ihor Gussak, NewCardio's Chief Medical Officer, commented, "We were delighted with the significant improvement in measurement variability and study power that we observed in this investigation. We look forward to sharing this exciting data at this important conference, which is attended by cardiovascular safety experts from regulatory bodies, pharmaceutical companies, clinical research organizations and academia. The improvement conferred by our new automated ECG selection algorithm offers sponsors the opportunity to reduce the number of subjects in a study without sacrificing study power, which may result in substantial cost savings. The new algorithm is a powerful extension of our platform technology, and further demonstrates NewCardio's ability to add value to every ECG."
Vincent Renz, CEO of NewCardio, commented, "These study results represent yet another important and substantial technological innovation for QTinno that further differentiates QTinno from competition and solidifies QTinno's position as the industry's leading automated solution for drug safety studies. This is further evidence that NewCardio will continue to enhance QTinno in order to eliminate the manual, labor intensive procedures employed in the current cardiac safety methodologies, which typically affect the drug sponsors through longer timelines, higher costs and from our findings, lower quality. We believe that our latest innovation, intelligent ECG extraction, will provide additional gains that will allow the pharmaceutical industry to complete higher quality cardiac safety analysis faster, more reliably, and at significantly lower cost."
Well, they released the annual! An uplisting should soon follow, correct?
http://www.otcmarkets.com/stock/IGSM/financials